{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:02:08Z","timestamp":1790654528132,"version":"4.1.0"},"reference-count":152,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e1 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00204","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T11:26:03Z","timestamp":1583493963000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["The Delay in the Licensing of Protozoal Vaccines: A Comparative History"],"prefix":"10.3389","volume":"11","author":[{"given":"Clarisa Beatriz","family":"Palatnik-de-Sousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirlei","family":"Nico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1016\/j.vaccine.2010.03.002","article-title":"Improving the public health: the U.S. recommendation for universal influenza immunization","volume":"28","author":"Poland","year":"2010","journal-title":"Vaccine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nri3694","article-title":"From empiricism to rational design: a personal perspective of the evolution of vaccine development","volume":"14","author":"De Gregorio","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccines for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Vaccine."},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/00034983.1995.11813017","article-title":"Vaccines against leishmaniasis","volume":"89","author":"Modabber","year":"1995","journal-title":"Ann Trop Med Parasitol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3389\/fimmu.2018.00826","article-title":"Editorial: epitope discovery and synthetic vaccine design","volume":"9","author":"Palatnik-de-Sousa","year":"2018","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3389\/fmicb.2016.00467","article-title":"Post-genomics and vaccine improvement for leishmania","volume":"7","author":"Seyed","year":"2016","journal-title":"Front Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0020-7519(03)00053-5","article-title":"Recent advances in veterinary vaccine adjuvants","volume":"33","author":"Singh","year":"2003","journal-title":"Int J Parasitol"},{"key":"B8","unstructured":"RoyJ\n          Ann Illustrated History of Samllpox and Its Eradication\u2014Google Search"},{"key":"B9","first-page":"197","volume-title":"Saul Adler, Pioneer of Tropical Medicine: A Biography","author":"Gavron","year":"1997"},{"key":"B10","unstructured":"SantosNSDO\n            RomanosMTV\n            WiggMD\n          Livro\u2014Introdu\u00e7\u00e3o \u00c0 Virologia Humana"},{"key":"B11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3109\/08830185.2015.1082177","article-title":"Anti-infectious human vaccination in historical perspective","volume":"35","author":"D'Amelio","year":"2016","journal-title":"Int Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9244","DOI":"10.1128\/JVI.00945-06","article-title":"Genome of horsepox virus","volume":"80","author":"Tulman","year":"2006","journal-title":"J Virol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/462709a","article-title":"Cattle disease faces total wipeout","volume":"462","author":"Gilbert","year":"2009","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.20506\/rst.36.2.2676","article-title":"Rinderpest eradication: challenges for remaining disease free and implications for future eradication efforts","volume":"36","author":"Hamilton","year":"2017","journal-title":"Rev Sci Tech Int Off Epizoot."},{"key":"B15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S1286-4579(03)00075-3","article-title":"Louis pasteur (1822\u20131895)","volume":"5","author":"Bordenave","year":"2003","journal-title":"Microbes Infect"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00117","DOI":"10.1128\/mBio.00117-17","article-title":"Remembering emil von behring: from tetanus treatment to antibody cooperation with phagocytes","volume":"8","author":"Kaufmann","year":"2017","journal-title":"mBio"},{"key":"B17","doi-asserted-by":"publisher","first-page":"MGM2-0028","DOI":"10.1128\/microbiolspec.MGM2-0028-2013","article-title":"BCG vaccines","volume":"2","author":"Tran","year":"2014","journal-title":"Microbiol Spectr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1203\/01.PDR.0000106317.36875.6A","article-title":"Childhood vaccine development: an overview","volume":"55","author":"Baker","year":"2004","journal-title":"Pediatr Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","article-title":"Yellow fever live attenuated vaccine: a very successful live attenuated vaccine but still we have problems controlling the disease","volume":"35","author":"Barrett","year":"2017","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.11622\/smedj.2019002","article-title":"Jonas salk (1914\u20131995): a vaccine against polio","volume":"60","author":"Tan","year":"2019","journal-title":"Singapore Med J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"398","author":"Van Damme","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"B22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1080\/21645515.2017.1289301","article-title":"HPV vaccines: global perspectives","volume":"13","author":"Gupta","year":"2017","journal-title":"Hum Vaccines Immunother."},{"key":"B24","first-page":"74","article-title":"[The classic work of girolamo fracastoro (on the 450th anniversary of the publication of his book \u201cde contagione et de contagiosis morbis et curatione\u201d)]","volume":"317","author":"Gribanov","year":"1996","journal-title":"Voen Med Zh"},{"key":"B25","unstructured":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.PoH-0006-2015","article-title":"Paleopathology and paleomicrobiology of malaria","volume":"4","author":"Nerlich","year":"2016","journal-title":"Microbiol Spectr"},{"key":"B27","unstructured":""},{"key":"B28","unstructured":""},{"key":"B29","unstructured":""},{"key":"B30","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fmicb.2014.00586","article-title":"Novel approaches to identify protective malaria vaccine candidates","volume":"5","author":"Chia","year":"2014","journal-title":"Front Microbiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1756-3305-4-197","article-title":"One health: the global challenge of epidemic and endemic leishmaniasis","volume":"4","author":"Palatnik-de-Sousa","year":"2011","journal-title":"Parasit Vectors"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3389\/fimmu.2018.01397","article-title":"The US military commitment to vaccine development: a century of successes and challenges","volume":"9","author":"Ratto-Kim","year":"2018","journal-title":"Front Immunol"},{"key":"B33","unstructured":"OWJC: Why are Drugs More Profitable Than Vaccines?\n            HaliouaC\n          (Health Economics Working Paper)2018"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.provac.2015.05.001","article-title":"Editorial: preventive vaccination","volume":"9","author":"de Sousa","year":"2015","journal-title":"Procedia Vaccinol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/cid\/ciu954","article-title":"Vaccines against malaria","volume":"60","author":"Ouattara","year":"2015","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"B36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s13063-019-3391-7","article-title":"RTS,S malaria vaccine pilot studies: addressing the human realities in large-scale clinical trials","volume":"20","author":"van den Berg","year":"2019","journal-title":"Trials"},{"key":"B37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/imm.12780","article-title":"Vaccine candidate discovery for the next generation of malaria vaccines","volume":"152","author":"Tuju","year":"2017","journal-title":"Immunology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1126\/science.102.2643.202","article-title":"Immunization of rhesus monkeys against malarial infection (P. knowlesi) with killed parasites and adjuvants","volume":"102","author":"Freund","year":"1945","journal-title":"Science"},{"key":"B39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00000441-197309000-00002","article-title":"Immunization of man against sporozite-induced falciparum malaria","volume":"266","author":"Clyde","year":"1973","journal-title":"Am J Med Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e00479","DOI":"10.1128\/IAI.00479-17","article-title":"Controlled human malaria infection: applications, advances, and challenges","volume":"86","author":"Stanisic","year":"2017","journal-title":"Infect Immun"},{"key":"B41","unstructured":"Malaria Transmission Blocking Vaccines: An Ideal Public Good."},{"key":"B42","unstructured":"Guidelines for the Evaluation of Plasmodium Falciparum Vaccines in Populations Exposed to Natural Infection"},{"key":"B43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/192733a0","article-title":"Gamma-globulin and acquired immunity to human malaria","volume":"192","author":"Cohen","year":"1961","journal-title":"Nature."},{"key":"B44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.6204383","article-title":"Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum","volume":"225","author":"Dame","year":"1984","journal-title":"Science."},{"key":"B45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","year":"2014","journal-title":"PLoS Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.vaccine.2005.01.142","article-title":"Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the walter reed army institute of research","volume":"23","author":"Heppner","year":"2005","journal-title":"Vaccine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1016\/j.vaccine.2005.12.041","article-title":"A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S\/AS02A and MVA-CS","volume":"24","author":"Dunachie","year":"2006","journal-title":"Vaccine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4269\/ajtmh.2003.68.97","article-title":"Protective efficacy of the RTS,S\/AS02 Plasmodium falciparum malaria vaccine is not strain specific","volume":"68","author":"Alloueche","year":"2003","journal-title":"Am J Trop Med Hyg."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1371\/journal.pctr.0010005","article-title":"RTS,S\/AS02A malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection","volume":"1","author":"Enosse","year":"2006","journal-title":"PLoS Clin Trials"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e7849","DOI":"10.1371\/journal.pone.0007849","article-title":"Impact of RTS,S\/AS02(A) and RTS,S\/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial","volume":"4","author":"Waitumbi","year":"2009","journal-title":"PLoS ONE"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.1371\/journal.pone.0000707","article-title":"Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"2","author":"Bejon","year":"2007","journal-title":"PLoS ONE"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e12294","DOI":"10.1371\/journal.pone.0012294","article-title":"Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with plasmodium berghei","volume":"5","author":"Bergmann-Leitner","year":"2010","journal-title":"PLoS ONE."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tmaid.2013.01.006","article-title":"The malaria vaccine\u2014status quo 2013","volume":"11","author":"Heppner","year":"2013","journal-title":"Travel Med Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/14760584.2019.1561289","article-title":"Malaria vaccines in the eradication era: current status and future perspectives","volume":"18","author":"Wilson","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"B56","unstructured":""},{"key":"B57","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1473-3099(19)30300-7","article-title":"Long-term incidence of severe malaria following RTS,S\/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial","volume":"19","author":"Tinto","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B58","unstructured":""},{"key":"B59","unstructured":"Global Technical Strategy for Malaria 2016\u20132030"},{"key":"B60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4269\/ajtmh.1991.45.297","article-title":"Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria","volume":"45","author":"Sabchareon","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"B61","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1086\/339342","article-title":"A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J Infect Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1086\/509806","article-title":"Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection","volume":"195","author":"Polley","year":"2007","journal-title":"J Infect Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1016\/j.vaccine.2018.08.033","article-title":"Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: a phase 1 dose-escalation study in healthy adults","volume":"36","author":"Chichester","year":"2018","journal-title":"Vaccine."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0163144","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and immunogenicity of Pfs25-EPA\/alhydrogel\u00ae, a transmission blocking vaccine against Plasmodium falciparum: an open label study in malaria na\u00efve adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS ONE."},{"key":"B65","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13071-019-3470-3","article-title":"Strong concordance between percent inhibition in oocyst and sporozoite intensities in a Plasmodium falciparum standard membrane-feeding assay","volume":"12","author":"Miura","year":"2019","journal-title":"Parasit Vectors"},{"key":"B66","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-018-0064-6","article-title":"Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development","volume":"3","author":"Ch\u00eane","year":"2018","journal-title":"NPJ Vaccines"},{"key":"B67","unstructured":""},{"key":"B68","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e0006559","DOI":"10.1371\/journal.pntd.0006559","article-title":"The burden of neglected tropical diseases in Brazil, 1990-2016: a subnational analysis from the global burden of disease study 2016","volume":"12","author":"Martins-Melo","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0129418","DOI":"10.1371\/journal.pone.0129418","article-title":"Epidemiology of imported leishmaniasis in Italy: implications for a European endemic country","volume":"10","author":"Di Muccio","year":"2015","journal-title":"PLoS ONE."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e0186372","DOI":"10.1371\/journal.pone.0186372","article-title":"Efficacies of prevention and control measures applied during an outbreak in Southwest Madrid, Spain","volume":"12","author":"Sev\u00e1","year":"2017","journal-title":"PLoS ONE"},{"key":"B73","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13071-015-0789-2","article-title":"Ecological aspects and molecular detection of leishmania DNA ross (Kinetoplastida: Trypanosomatidae) in phlebotomine sandflies (Diptera: Psychodidae) in terra firme and v\u00e1rzea environments in the middle Solim\u00f5es Region, Amazonas State, Brazil","volume":"8","author":"Pereira","year":"2015","journal-title":"Parasit Vectors."},{"key":"B74","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3389\/fimmu.2012.00251","article-title":"Immunobiology of visceral leishmaniasis","volume":"3","author":"Kumar","year":"2012","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.pt.2012.08.007","article-title":"Canine leishmaniosis in the old and new worlds: unveiled similarities and differences","volume":"28","author":"Dantas-Torres","year":"2012","journal-title":"Trends Parasitol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4269\/ajtmh.1996.55.125","article-title":"The logic of visceral leishmaniasis control","volume":"55","author":"Dye","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"B77","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1016\/j.vaccine.2009.03.045","article-title":"Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with leishmune in Brazilian endemic areas","volume":"27","author":"Palatnik-de-Sousa","year":"2009","journal-title":"Vaccine"},{"key":"B78","first-page":"423","article-title":"Leishmaniasis vaccine candidates for development: a global overview","volume":"123","author":"Khamesipour","year":"2006","journal-title":"Ind J Med Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/S0140-6736(00)03128-7","article-title":"Autoclaved leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan","volume":"356","author":"Khalil","year":"2000","journal-title":"Lancet Lond Engl"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2015.03.017","article-title":"Vaccines for visceral leishmaniasis: a review","volume":"422","author":"Jain","year":"2015","journal-title":"J Immunol Methods"},{"key":"B81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/ijpvm.IJPVM_116_18","article-title":"Leishmania vaccines entered in clinical trials: a review of literature","volume":"10","author":"Moafi","year":"2019","journal-title":"Int J Prev Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1016\/j.vaccine.2019.04.092","article-title":"Visceral leishmaniasis: an overview of vaccine adjuvants and their applications","volume":"37","author":"Ratnapriya","year":"2019","journal-title":"Vaccine"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1016\/j.vaccine.2008.07.029","article-title":"Immunogenicity assay of the leishmune vaccine against canine visceral leishmaniasis in Brazil","volume":"26","author":"Borja-Cabrera","year":"2008","journal-title":"Vaccine."},{"key":"B84","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1586\/14760584.7.6.833","article-title":"FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine","volume":"7","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"B85","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1016\/j.vaccine.2008.05.095","article-title":"Protective immunity against challenge with leishmania (leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein","volume":"26","author":"Fernandes","year":"2008","journal-title":"Vaccine."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e3213","DOI":"10.1371\/journal.pntd.0003213","article-title":"A randomised, double-blind, controlled efficacy trial of the LiESP\/QA-21 vaccine in na\u00efve dogs exposed to two Leishmania infantum transmission seasons","volume":"8","author":"Oliva","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.vaccine.2018.02.111","article-title":"A large-scale field randomized trial demonstrates safety and efficacy of the vaccine letifend\u00ae against canine leishmaniosis","volume":"36","author":"Fern\u00e1ndez Cotrina","year":"2018","journal-title":"Vaccine"},{"key":"B88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fimmu.2012.00069","article-title":"Vaccines for canine leishmaniasis","volume":"3","author":"Palatnik-de-Sousa","year":"2012","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1016\/j.vaccine.2006.02.034","article-title":"Acylated and deacylated saponins of quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis","volume":"24","author":"Oliveira-Freitas","year":"2006","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1128\/IAI.57.3.754-763.1989","article-title":"Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands","volume":"57","author":"Palatnik","year":"1989","journal-title":"Infect Immun"},{"key":"B91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0001-706X(93)90006-W","article-title":"Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the fucose-mannose ligand (FML)","volume":"53","author":"Palatnik-de-Sousa","year":"1993","journal-title":"Acta Trop."},{"key":"B92","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/BF00928181","article-title":"A new approach to the phylogeny of leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages","volume":"76","author":"Palatnik","year":"1990","journal-title":"Parasitol Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3389\/fimmu.2019.00813","article-title":"Nucleoside Hydrolase NH 36: a vital enzyme for the leishmania genus in the development of T-cell epitope cross-protective vaccines","volume":"10","author":"Palatnik-de-Sousa","year":"2019","journal-title":"Front Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1590\/S0037-86821996000200008","article-title":"The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar","volume":"29","author":"Palatnik de Sousa","year":"1996","journal-title":"Rev Soc Bras Med Trop."},{"key":"B95","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4269\/ajtmh.1999.61.296","article-title":"The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil","volume":"61","author":"Cabrera","year":"1999","journal-title":"Am J Trop Med Hyg."},{"key":"B96","first-page":"1311","article-title":"Transmission of visceral leishmaniasis by blood transfusion in hamsters","volume":"29","author":"Palatnik-de-Sousa","year":"1996","journal-title":"Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol"},{"key":"B97","first-page":"547","article-title":"Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML)","volume":"27","author":"Palatnik-de-Sousa","year":"1994","journal-title":"Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"23\u201324","DOI":"10.1016\/S0264-410X(01)00031-7","article-title":"Vaccination of Balb\/c mice against experimental visceral Leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani","volume":"19","author":"Paraguai de Souza","year":"2001","journal-title":"Vaccine"},{"key":"B99","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0264-410X(02)00444-9","article-title":"Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral Leishmaniasis","volume":"21","author":"Santos","year":"2002","journal-title":"Vaccine"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/S0264-410X(00)00339-X","article-title":"A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amaranto, RN)","volume":"19","author":"da Silva","year":"2000","journal-title":"Vaccine"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1016\/S0264-410X(02)00294-3","article-title":"Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S\u00e3o Gon\u00e7alo do Amarante, RN)","volume":"20","author":"Borja-Cabrera","year":"2002","journal-title":"Vaccine"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/S0264-410X(03)00046-X","article-title":"IgG1\/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral Leishmaniosis","volume":"21","author":"de Oliveira Mendes","year":"2003","journal-title":"Vaccine"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/S0264-410X(03)00032-X","article-title":"Protection in dogs against visceral Leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK","volume":"21","author":"Ramiro","year":"2003","journal-title":"Vaccine"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","article-title":"Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum","volume":"23","author":"Rafati","year":"2005","journal-title":"Vaccine"},{"key":"B105","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1365-3024.1995.tb00914.x","article-title":"Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites","volume":"17","author":"Deplazes","year":"1995","journal-title":"Parasite Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0304-4017(00)00446-5","article-title":"Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. evolution in the course of infection and after treatment","volume":"96","author":"Solano-Gallego","year":"2001","journal-title":"Vet Parasitol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0165-2427(98)00213-X","article-title":"Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis","volume":"67","author":"Nieto","year":"1999","journal-title":"Vet Immunol Immunopathol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/j.vaccine.2006.11.057","article-title":"Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil","volume":"25","author":"Parra","year":"2007","journal-title":"Vaccine."},{"key":"B110","doi-asserted-by":"publisher","first-page":"e0154757","DOI":"10.1371\/journal.pone.0154757","article-title":"Meta-analysis on randomized controlled trials of vaccines with QS-21 or ISCOMATRIX adjuvant: safety and tolerability","volume":"11","author":"Bigaeva","year":"2016","journal-title":"PLoS ONE"},{"key":"B111","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.vaccine.2009.09.071","article-title":"Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis","volume":"28","author":"Borja-Cabrera","year":"2010","journal-title":"Vaccine."},{"key":"B112","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine."},{"key":"B113","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1016\/j.vaccine.2005.05.011","article-title":"Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs","volume":"23","author":"Nogueira","year":"2005","journal-title":"Vaccine"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.vaccine.2005.11.061","article-title":"The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine","volume":"24","author":"Saraiva","year":"2006","journal-title":"Vaccine"},{"key":"B115","doi-asserted-by":"publisher","first-page":"16549","DOI":"10.1038\/s41598-018-34812-x","article-title":"A complete Leishmania donovani reference genome identifies novel genetic variations associated with virulence","volume":"8","author":"Lypaczewski","year":"2018","journal-title":"Sci Rep."},{"key":"B116","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2958.2010.07229.x","article-title":"Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein","volume":"77","author":"McCall","year":"2010","journal-title":"Mol Microbiol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1128\/IAI.71.7.3988-3994.2003","article-title":"Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection","volume":"71","author":"Coelho","year":"2003","journal-title":"Infect Immun"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1016\/S0264-410X(01)00023-8","article-title":"Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response","volume":"19","author":"Ghosh","year":"2001","journal-title":"Vaccine."},{"key":"B119","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","article-title":"Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections","volume":"20","author":"Ghosh","year":"2001","journal-title":"Vaccine."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e2853","DOI":"10.1371\/journal.pntd.0002853","article-title":"Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen","volume":"8","author":"Grimaldi","year":"2014","journal-title":"PLoS Negl Trop Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.vaccine.2016.03.019","article-title":"Field randomized trial to evaluate the efficacy of the Leish-Tec\u00ae vaccine against canine visceral leishmaniasis in an endemic area of Brazil","volume":"34","author":"Regina-Silva","year":"2016","journal-title":"Vaccine."},{"key":"B122","doi-asserted-by":"publisher","first-page":"e0185438","DOI":"10.1371\/journal.pone.0185438","article-title":"Field trial of efficacy of the Leish-tec\u00ae vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates","volume":"12","author":"Grimaldi","year":"2017","journal-title":"PLOS ONE."},{"key":"B123","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.1016\/j.vaccine.2018.08.087","article-title":"Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis","volume":"36","author":"Toepp","year":"2018","journal-title":"Vaccine"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.vaccine.2013.12.046","article-title":"Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis","volume":"32","author":"Fernandes","year":"2014","journal-title":"Vaccine."},{"key":"B125","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s13071-016-1752-6","article-title":"Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec\u00ae and Leishmune\u00ae vaccines against visceral leishmaniasis","volume":"9","author":"de","year":"2016","journal-title":"Parasit Vectors."},{"key":"B126","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.vetpar.2016.02.009","article-title":"Vaccination against canine leishmaniosis increases the phagocytic activity, nitric oxide production and expression of cell activation\/migration molecules in neutrophils and monocytes","volume":"220","author":"Moreira","year":"2016","journal-title":"Vet Parasitol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12917-015-0397-6","article-title":"One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis","volume":"11","author":"Costa-Pereira","year":"2015","journal-title":"BMC Vet Res"},{"key":"B128","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.vetimm.2009.12.008","article-title":"Diminished CD4+\/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis","volume":"135","author":"de Lima","year":"2010","journal-title":"Vet Immunol Immunopathol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.vaccine.2008.11.104","article-title":"T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune","volume":"27","author":"Ara\u00fajo","year":"2009","journal-title":"Vaccine"},{"key":"B130","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1297-9716-45-69","article-title":"The protective immune response produced in dogs after primary vaccination with the LiESP\/QA-21 vaccine (CaniLeish\u00ae) remains effective against an experimental challenge one year later","volume":"45","author":"Martin","year":"2014","journal-title":"Vet Res"},{"key":"B131","unstructured":""},{"key":"B132","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.vetpar.2015.01.003","article-title":"Canine Leishmania vaccines: still a long way to go","volume":"208","author":"Gradoni","year":"2015","journal-title":"Vet Parasitol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fvets.2019.00168","article-title":"Assessment of Vaccine-induced immunity against canine visceral leishmaniasis","volume":"6","author":"Moreno","year":"2019","journal-title":"Front Vet Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1128\/JCM.36.1.58-63.1998","article-title":"Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis","volume":"36","author":"Soto","year":"1998","journal-title":"J Clin Microbiol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"5964","DOI":"10.1016\/j.vaccine.2009.07.069","article-title":"The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection","volume":"27","author":"Carcel\u00e9n","year":"2009","journal-title":"Vaccine."},{"key":"B136","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1179\/146532806X152890","article-title":"Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study","volume":"26","author":"Khalil","year":"2006","journal-title":"Ann Trop Paediatr"},{"key":"B137","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0035-9203(03)90171-4","article-title":"Alum-precipitated autoclaved Leishmania major plus bacille calmette-gu\u00e9rrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers","volume":"97","author":"Kamil","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0264-410X(00)00401-1","article-title":"Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy sudanese volunteers","volume":"19","author":"Satti","year":"2001","journal-title":"Vaccine"},{"key":"B139","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0166-6851(02)00010-5","article-title":"Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis","volume":"120","author":"Santana","year":"2002","journal-title":"Mol Biochem Parasitol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3389\/fimmu.2018.00967","article-title":"NH36 and F3 antigen-primed dendritic cells show preserved migrating capabilities and CCR7 expression and F3 is effective in immunotherapy of visceral Leishmaniasis","volume":"9","author":"Nico","year":"2018","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejmech.2012.07.052","article-title":"Kinetics and docking studies of two potential new inhibitors of the nucleoside hydrolase from Leishmania donovani","volume":"56","author":"Renn\u00f3","year":"2012","journal-title":"Eur J Med Chem."},{"key":"B142","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fimmu.2014.00189","article-title":"Cross-protective immunity to leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains","volume":"5","author":"Nico","year":"2014","journal-title":"Front Immunol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1371\/journal.pntd.0000866","article-title":"Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response","volume":"4","author":"Nico","year":"2010","journal-title":"PLoS Negl Trop Dis."},{"key":"B144","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fimmu.2017.00100","article-title":"A chimera containing CD4+ and CD8+ T-cell epitopes of the Leishmania donovani nucleoside hydrolase (NH36) optimizes cross-protection against leishmania amazonesis infection","volume":"8","author":"Alves-Silva","year":"2017","journal-title":"Front Immunol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fimmu.2017.00227","article-title":"Leishmania donovani nucleoside hydrolase (NH36) domains induce T-cell cytokine responses in human visceral leishmaniasis","volume":"8","author":"Barbosa Santos","year":"2017","journal-title":"Front Immunol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol."},{"key":"B147","unstructured":""},{"key":"B148","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.provac.2012.04.009","article-title":"The leishmune\u00aes nucleoside hydrolase DNA vaccine as an aid in immunotherapy of canine visceral leishmaniasis","volume":"6","author":"Borja-Cabrera","year":"2012","journal-title":"Procedia Vaccinol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fimmu.2017.00750","article-title":"F1 Domain of the leishmania (leishmania) donovani Nucleoside hydrolase promotes a Th1 response in leishmania (leishmania) infantum cured patients and in asymptomatic individuals living in an endemic area of leishmaniasis","volume":"8","author":"Carrillo","year":"2017","journal-title":"Front Immunol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.1016\/j.vaccine.2011.09.126","article-title":"A1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model","volume":"29","author":"Jenikova","year":"2011","journal-title":"Vaccine"},{"key":"B151","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0169-4758(99)01623-3","article-title":"Giardia vaccination","volume":"16","author":"Olson","year":"2000","journal-title":"Parasitol Today Pers Ed."},{"key":"B152","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.vetpar.2007.01.013","article-title":"Efficacy of vaccination in preventing giardiasis in calves","volume":"146","author":"Uehlinger","year":"2007","journal-title":"Vet Parasitol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00204\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T11:26:07Z","timestamp":1583493967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00204\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":152,"alternative-id":["10.3389\/fimmu.2020.00204"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00204","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"article-number":"204"}}